Prostaglandin E2 upregulates β1 integrin expression via the E prostanoid 1 receptor/nuclear factor κ‑light‑chain‑enhancer of activated B cells pathway in non‑small‑cell lung cancer cells

Bai,Xiaoming; Yang,Qinyi; Shu,Wei; Wang,Jie; Zhang,Li; Ma,Juan; Xia,Shukai; Zhang,Min; Cheng,Shanyu; Wang,Yipin; Leng,Jing

doi:10.3892/mmr.2014.2000

Prostaglandin E2 upregulates β1 integrin expression via the E prostanoid 1 receptor/nuclear factor κ‑light‑chain‑enhancer of activated B cells pathway in non‑small‑cell lung cancer cells

Authors:
- Xiaoming Bai
- Qinyi Yang
- Wei Shu
- Jie Wang
- Li Zhang
- Juan Ma
- Shukai Xia
- Min Zhang
- Shanyu Cheng
- Yipin Wang
- Jing Leng
View Affiliations

Affiliations: Cancer Center, Department of Pathology, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Periodontal, Institute of Stomatology, The Stomatological Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Pathology, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China
Published online on: February 28, 2014 https://doi.org/10.3892/mmr.2014.2000
Pages: 1729-1736

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prostaglandin E2 (PGE2) E prostanoid (EP)1 receptor shown to be associated with lung cancer cell invasion. However, the mechanism of EP1 receptor‑mediated cell migration remains to be elucidated. β1 integrin is an essential regulator of the tumorigenic properties of non‑small‑cell lung carcinoma (NSCLC) cells. To date, little is known regarding the association between the EP1 receptor and β1 integrin expression. The present study investigated the effect of EP1 receptor activation on β1 integrin expression and cell migration in NSCLC cells. A total of 34 patients with clinical diagnosis of NSCLC and 10 patients with benign disease were recruited for the present study. The expression levels of the EP1 receptor and β1 integrin expression were studied in resected lung tissue using immunohistochemistry. A statistical analysis was performed using Stata se12.0 software. The effects of PGE2, EP1 agonist 17‑phenyl trinor‑PGE2 (17‑PT‑PGE2) and the nuclear factor κ‑B (NF‑κB) inhibitor on β1 integrin expression were investigated on A549 cells. The expression of β1 integrin and the phosphorylation of NF‑κB‑p65 Ser536 was investigated by western blot analysis. Cell migration was assessed by a transwell assay. The results demonstrated that β1 integrin and EP1 receptor expression exhibited a positive correlation of evident significance in the 44 samples. The in vitro migration assay revealed that cell migration was increased by 30% when the cells were treated with 5 µM 17‑PT‑PGE2 and that the pre‑treatment of β1 integrin monoclonal antibody inhibited 17‑PT‑PGE2‑mediated cell migration completely. PGE2 and 17‑PT‑PGE2 treatment increased β1 integrin expression. RNA interference against the EP1 receptor blocked the PGE2‑mediated β1 integrin expression in A549 cells. Treatment with 17‑PT‑PGE2 induced NF‑κB activation, and the selective NF‑κB inhibitor pyrrolidinedithiocarbamate inhibited 17‑PT‑PGE2‑mediated β1 integrin expression. In conclusion, the present study indicated that the PGE2 EP1 receptor regulates β1 integrin expression and cell migration in NSCLC cells by activating the NF‑κB signaling pathway. Targeting the PGE2/EP1/β1 integrin signaling pathway may aid in the development of new therapeutic strategies for the prevention and treatment of this type of cancer.

View Figures

View References

1	Gordon IO, Sitterding S, Mackinnon AC and Husain AN: Update in neoplastic lung diseases and mesothelioma. Arch Pathol Lab Med. 133:1106–1115. 2009.PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
3	Mehran RJ: Lung cancer: an update on current surgical strategies. Tex Heart Inst J. 39:844–845. 2012.PubMed/NCBI
4	Mao JT, Cui X, Reckamp K, et al: Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer. 7:30–39. 2005. View Article : Google Scholar : PubMed/NCBI
5	Dohadwala M, Batra RK, Luo J, et al: Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem. 277:50828–50833. 2002. View Article : Google Scholar
6	Krysan K, Reckamp KL, Dalwadi H, et al: Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res. 65:6275–6281. 2005. View Article : Google Scholar
7	Oshima H and Oshima M: The role of PGE2-associated inflammatory responses in gastric cancer development. Semin Immunopathol. 35:139–150. 2013. View Article : Google Scholar : PubMed/NCBI
8	Li Z, Zhang Y, Kim WJ and Daaka Y: PGE2 promotes renal carcinoma cell invasion through activated RaIA. Oncogene. 32:1408–1415. 2013. View Article : Google Scholar : PubMed/NCBI
9	Karavitis J, Hix LM, Shi YH, Schultz RF, Khazaie K and Zhang M: Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. PLoS One. 7:e463422012. View Article : Google Scholar : PubMed/NCBI
10	Hazra S and Dubinett SM: Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells. Prostaglandins Leukot Essent Fatty Acids. 77:51–58. 2007. View Article : Google Scholar : PubMed/NCBI
11	Ho MY, Liang SM, Hung SW and Liang CM: MIG-7 controls COX-2/PGE2-mediated lung cancer metastasis. Cancer Res. 73:439–449. 2013. View Article : Google Scholar : PubMed/NCBI
12	Boie Y, Stocco R, Sawyer N, et al: Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 340:227–241. 1997. View Article : Google Scholar : PubMed/NCBI
13	Liu H, Yang Y, Xiao J, et al: COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer. Anat Rec (Hoboken). 293:1838–1846. 2010. View Article : Google Scholar : PubMed/NCBI
14	Su JL, Shih JY, Yen ML, et al: Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res. 64:554–564. 2004. View Article : Google Scholar : PubMed/NCBI
15	Schuppan D and Ocker M: Integrin-mediated control of cell growth. Hepatology. 38:289–291. 2003. View Article : Google Scholar
16	Yao ES, Zhang H, Chen YY, et al: Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 67:659–664. 2007. View Article : Google Scholar : PubMed/NCBI
17	Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Heino J and Pyrhönen S: Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma. Melanoma Res. 14:29–37. 2004. View Article : Google Scholar : PubMed/NCBI
18	Müller-Klingspor V, Hefler L, Obermair A, et al: Prognostic value of beta1-integrin (=CD29) in serous adenocarcinomas of the ovary. Anticancer Res. 21:2185–2188. 2001.
19	Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR and Bellis SL: Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res. 65:4645–4652. 2005. View Article : Google Scholar : PubMed/NCBI
20	Fong YC, Hsu SF, Wu CL, et al: Transforming growth factor-beta1 increases cell migration and beta1 integrin up-regulation in human lung cancer cells. Lung Cancer. 64:13–21. 2009. View Article : Google Scholar : PubMed/NCBI
21	Morello V, Cabodi S, Sigismund S, et al: beta1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene. 30:4087–4096. 2011. View Article : Google Scholar : PubMed/NCBI
22	Zhang PF, Zeng GQ, Yi LZ, et al: Identification of integrin β1 as a prognostic biomarker for human lung adenocarcinoma using 2D-LCMS/MS combined with iTRAQ technology. Oncol Rep. 30:341–349. 2013.
23	Han S, Sidell N, Roser-Page S and Roman J: Fibronectin stimulates human lung carcinoma cell growth by inducing cyclooxygenase-2 (COX-2) expression. Int J Cancer. 111:322–331. 2004. View Article : Google Scholar : PubMed/NCBI
24	Pierro E, Minici F, Alesiani O, et al: In vitro regulation of beta1 and beta3 integrin subunits in endometrial epithelial cells from normal endometrium. Am J Reprod Immunol. 49:373–376. 2003. View Article : Google Scholar : PubMed/NCBI
25	Mayoral R, Fernández-Martínez A, Boscá L and Martín-Sanz P: Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis. 26:753–761. 2005. View Article : Google Scholar : PubMed/NCBI
26	Liu JF, Fong YC, Chang CS, et al: Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells. Mol Cancer. 9:432010. View Article : Google Scholar : PubMed/NCBI
27	Sun Q, Yao X, Ning Y, Zhang W, Zhou G and Dong Y: Overexpression of response gene to complement 32 (RGC32) promotes cell invasion and induces epithelial-mesenchymal transition in lung cancer cells via the NF-κB signaling pathway. Tumour Biol. 34:2995–3002. 2013.PubMed/NCBI
28	Falcone D, Gallelli L, Di Virgilio A, et al: Effects of simvastatin and rosuvastatin on RAS protein, matrix metalloproteinases and NF-κB in lung cancer and in normal pulmonary tissues. Cell Prolif. 46:172–182. 2013.PubMed/NCBI
29	Abrahao AC, Castilho RM, Squarize CH, Molinolo AA, dos Santos-Pinto D Jr and Gutkind JS: A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. Oral Oncol. 46:880–887. 2010. View Article : Google Scholar : PubMed/NCBI
30	Leng J, Han C, Demetris AJ, Michalopoulos GK and Wu T: Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology. 38:756–768. 2003. View Article : Google Scholar : PubMed/NCBI
31	Hussain T, Gupta S and Mukhtar H: Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. 191:125–135. 2003. View Article : Google Scholar : PubMed/NCBI
32	Zhao QT, Yue SQ, Cui Z, et al: Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci. 80:484–492. 2007. View Article : Google Scholar : PubMed/NCBI
33	Bai XM, Zhang W, Liu NB, et al: Focal adhesion kinase: important to prostaglandin E2-mediated adhesion, migration and invasion in hepatocellular carcinoma cells. Oncol Rep. 21:129–136. 2009.PubMed/NCBI
34	Han C and Wu T: Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem. 280:24053–24063. 2005. View Article : Google Scholar
35	Buchanan FG, Wang D, Bargiacchi F and DuBois RN: Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 278:35451–35457. 2003. View Article : Google Scholar : PubMed/NCBI
36	Sun B, Rong R, Jiang H, et al: Prostaglandin E2 receptor EP1 phosphorylate CREB and mediates MMP2 expression in human cholangiocarcinoma cells. Mol Cell Biochem. 378:195–203. 2013. View Article : Google Scholar : PubMed/NCBI
37	Bai XM, Jiang H, Ding JX, et al: Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells. Life Sci. 86:214–223. 2010. View Article : Google Scholar : PubMed/NCBI
38	Zhang L, Jiang L, Sun Q, et al: Prostaglandin E2 enhances mitogen-activated protein kinase/Erk pathway in human cholangiocarcinoma cells: involvement of EP1 receptor, calcium and EGF receptors signaling. Mol Cell Biochem. 305:19–26. 2007. View Article : Google Scholar
39	Cary LA and Guan JL: Focal adhesion kinase in integrin-mediated signaling. Front Biosci. 4:D102–D113. 1999. View Article : Google Scholar : PubMed/NCBI
40	Missan DS and DiPersio M: Integrin control of tumor invasion. Crit Rev Eukaryot Gene Expr. 22:309–324. 2012. View Article : Google Scholar : PubMed/NCBI
41	Zhang H, Ozaki I, Mizuta T, et al: Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. Cancer. 95:896–906. 2002. View Article : Google Scholar
42	Sethi T, Rintoul RC, Moore SM, et al: Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med. 5:662–668. 1999. View Article : Google Scholar : PubMed/NCBI
43	Ju L and Zhou C: Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer. Cancer Cell Int. 13:152013. View Article : Google Scholar : PubMed/NCBI
44	Ju L, Zhou C, Li W and Yan L: Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. J Cell Biochem. 111:1565–1574. 2010. View Article : Google Scholar : PubMed/NCBI
45	Yazawa K, Tsuno NH, Kitayama J, et al: Selective inhibition of cyclooxygenase-2 inhibits colon cancer cell adhesion to extracellular matrix by decreased expression of beta1 integrin. Cancer Sci. 96:93–99. 2005. View Article : Google Scholar : PubMed/NCBI
46	Bai X, Wang J, Zhang L, et al: Prostaglandin E₂ receptor EP1-mediated phosphorylation of focal adhesion kinase enhances cell adhesion and migration in hepatocellular carcinoma cells. Int J Oncol. 42:1833–1841. 2013.
47	Tang CH, Yang RS and Fu WM: Prostaglandin E2 stimulates fibronectin expression through EP1 receptor, phospholipase C, protein kinase Calpha, and c-Src pathway in primary cultured rat osteoblasts. J Biol Chem. 280:22907–22916. 2005. View Article : Google Scholar
48	Chen F, Beezhold K and Castranova V: Tumor promoting or tumor suppressing of NF-kappa B, a matter of cell context dependency. Int Rev Immunol. 27:183–204. 2008. View Article : Google Scholar : PubMed/NCBI
49	Sen R and Smale ST: Selectivity of the NF-{kappa}B response. Cold Spring Harb Perspect Biol. 2:a0002572010.
50	Okamoto T, Sanda T and Asamitsu K: NF-kappa B signaling and carcinogenesis. Curr Pharm Des. 13:447–462. 2007. View Article : Google Scholar : PubMed/NCBI
51	Ji R, Sanchez CM, Chou CL, Chen XB, Woodward DF and Regan JW: Prostanoid EP₁ receptors mediate up-regulation of the orphan nuclear receptor Nurr¹ by cAMP-independent activation of protein kinase A, CREB and NF-κB. Br J Pharmacol. 166:1033–1046. 2012.PubMed/NCBI
52	Melisi D and Chiao PJ: NF-kappa B as a target for cancer therapy. Expert Opin Ther Targets. 11:133–144. 2007. View Article : Google Scholar : PubMed/NCBI